Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Operating Leases: 2022-2025

Historic Operating Leases for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $632,000.

  • Corvus Pharmaceuticals' Operating Leases rose 78.53% to $632,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $632,000, marking a year-over-year increase of 78.53%. This contributed to the annual value of $937,000 for FY2024, which is 31.80% down from last year.
  • Corvus Pharmaceuticals' Operating Leases amounted to $632,000 in Q3 2025, which was down 13.19% from $728,000 recorded in Q2 2025.
  • Corvus Pharmaceuticals' Operating Leases' 5-year high stood at $2.3 million during Q1 2022, with a 5-year trough of $354,000 in Q3 2023.
  • Over the past 3 years, Corvus Pharmaceuticals' median Operating Leases value was $728,000 (recorded in 2025), while the average stood at $790,273.
  • In the last 5 years, Corvus Pharmaceuticals' Operating Leases slumped by 79.04% in 2023 and then soared by 78.53% in 2025.
  • Over the past 4 years, Corvus Pharmaceuticals' Operating Leases (Quarterly) stood at $1.4 million in 2022, then grew by 0.07% to $1.4 million in 2023, then slumped by 31.80% to $937,000 in 2024, then spiked by 78.53% to $632,000 in 2025.
  • Its Operating Leases was $632,000 in Q3 2025, compared to $728,000 in Q2 2025 and $834,000 in Q1 2025.